Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Cemiplimab in Resected Stage II-IIIA NSCLC
NCT06931717Phase 3Recruiting
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Jan 2026
- Primary completion
- Mar 2029
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Experimental Arm: Cemiplimab with Control Arm: Observation (2 arms). Primary endpoint: Disease-Free Survival at 59 months. Started Jan 2026; status: recruiting.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06931717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06931717.